Condition: Advanced Malignant Solid Tumors · Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd.
This is an open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1010 and preliminary anti-tumor efficacy in advanced malignant solid tumor subjects
This description comes directly from the study's public registry record.
Yan Shi · 0512-66526166 · shiy@genequantum.com
Always discuss trial participation with your own doctor first.
| Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute | Beijing, China | Recruiting |
| Department of Medical Oncology, Harbin Medical University Cancer Hospital | Harbin, China | Recruiting |
| Tianjin medical university cancer institute & hospital | Tianjin, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06464055